TY - JOUR
T1 - Targeted Screening for Congenital Cytomegalovirus in the Newborn Hearing Screening Program
T2 - A Population-Based Cohort Study
AU - Karvig, Luana Uchoa
AU - Pedersen, Emilie Luppescu
AU - Jordan, Karina
AU - Schmidt, Lisbeth Samsø
AU - Larsen, Lærke Vinge
AU - Poulsen, Anja
AU - Bille, Michael
AU - Carlsen, Emma Louise Malchau
AU - Smith, Birgitte
AU - Hansen, Bo Mølholm
AU - Hvilsted, Kirsten Fenger
AU - Moritz, Janko
AU - Jensen, Lise Heilmann
AU - Stanchev, Hristo
AU - Nielsen, Xiaohui Chen
AU - Zaharova, Tatjana
AU - Vestergaard, Dorthe
AU - Rytter, Maren Johanne Heilskov
AU - Nygaard, Ulrikka
AU - Lund Andersen, Stine Maria
N1 - © 2025 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.
PY - 2025/10/14
Y1 - 2025/10/14
N2 - AIM: To diagnose newborn infants with congenital cytomegalovirus (cCMV) related sensorineural hearing loss (SNHL) within the critical four-week window for initiating antiviral treatment, we aimed to determine the number needed to test (NNT) for cCMV among newborn infants failing the neonatal hearing screening.METHOD: A population-based multicenter cohort study included newborn infants in East Denmark who failed two hearing screening tests and underwent saliva CMV screening between November 2021 and May 2024. The NNT was calculated as the inverse of the absolute detection rate of cCMV-related SNHL in this cohort.RESULTS: A total of 484 infants with hearing screening failure were tested for cCMV. Of these, 27 (5.6%) were CMV positive in saliva and 7 (1.5%) were confirmed to have cCMV in urine, blood, or dried blood spots. Six (85.7%) of 7 infants with cCMV and initial hearing screening failure had normal hearing at follow-up, leaving 1 (0.2%) of 484 with cCMV-related SNHL and an NNT of 484 (95% CI 87-20 000).CONCLUSION: In our setting, targeted screening for cCMV resulted in a high NNT of almost 500 to identify one newborn infant with cCMV-related SNHL, reflecting a low incidence of cCMV-related SNHL and a high risk of false-positive hearing screening.
AB - AIM: To diagnose newborn infants with congenital cytomegalovirus (cCMV) related sensorineural hearing loss (SNHL) within the critical four-week window for initiating antiviral treatment, we aimed to determine the number needed to test (NNT) for cCMV among newborn infants failing the neonatal hearing screening.METHOD: A population-based multicenter cohort study included newborn infants in East Denmark who failed two hearing screening tests and underwent saliva CMV screening between November 2021 and May 2024. The NNT was calculated as the inverse of the absolute detection rate of cCMV-related SNHL in this cohort.RESULTS: A total of 484 infants with hearing screening failure were tested for cCMV. Of these, 27 (5.6%) were CMV positive in saliva and 7 (1.5%) were confirmed to have cCMV in urine, blood, or dried blood spots. Six (85.7%) of 7 infants with cCMV and initial hearing screening failure had normal hearing at follow-up, leaving 1 (0.2%) of 484 with cCMV-related SNHL and an NNT of 484 (95% CI 87-20 000).CONCLUSION: In our setting, targeted screening for cCMV resulted in a high NNT of almost 500 to identify one newborn infant with cCMV-related SNHL, reflecting a low incidence of cCMV-related SNHL and a high risk of false-positive hearing screening.
KW - Polymerase-chain-reaction
KW - Infection
KW - Cmv
KW - Feasibility
KW - Prevalence
KW - Children
U2 - 10.1111/apa.70326
DO - 10.1111/apa.70326
M3 - Article
C2 - 41088543
SN - 0803-5253
JO - Acta Paediatrica, International Journal of Paediatrics
JF - Acta Paediatrica, International Journal of Paediatrics
ER -